Dysfunction of circadian clock component PERIOD2 in oncogenic cells confers chemoresistance by up-regulation of Aldh3a1 gene
Ontology highlight
ABSTRACT: Disruption of circadian rhythms is implicated in increasing the risk of cancer development. The Period2 (Per2) gene is one of the major components of mammalian circadian clock, which plays a key role in controlling the circadian rhythms in physiology and behavior. PER2 also has tumor suppression function, but its role in the regulation of susceptibility to chemotherapeutic drugs remains unclear. In this study, we identified up-regulation of Aldehyde dehydrogenase 3a1 (Aldh3a1) gene in oncogenic transformed mouse embryo fibroblasts prepared from Per2-mutant (Per2m/m) mice, which were associated with the resistance against chemotherapeutic drugs. Co-expression of H-rasV12 and SV40 large T antigen induced malignant transformation of both wild-type and Per2m/m cells, but the cytotoxic effects of methotrexate, gemcitabine, etoposide, vincristine, and oxaliplatin were significantly alleviated in oncogenic transformed Per2m/m cells. Although introduction of oncogenes increased the expression of Aldh3a1 in both wild-type and Per2m/m cells, the levels of ALDH3A1 protein in oncogenic transformed Per2m/m cells were 10-fold higher than those in wild-type cells. Elevated ALDH3A1 levels in oncogenic transformed Per2m/m cells were sufficient to prevent chemotherapeutic drug-induced production of reactive oxygen species. Consequently, suppression of Aldh3a1 expression by siRNA relived chemoresistance of Per2m/m cells. These results suggest an uncovered role for PER2 in the development of multiple drug resistance and offers new therapeutic strategies for treatment of cancers.
ORGANISM(S): Mus musculus
PROVIDER: GSE113242 | GEO | 2018/10/10
REPOSITORIES: GEO
ACCESS DATA